Status:
COMPLETED
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
Lead Sponsor:
Providence Health & Services
Collaborating Sponsors:
Microstein, LLC
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
FEMALE
18-45 years
Brief Summary
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
Detailed Description
The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX...
Eligibility Criteria
Inclusion
- Subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication.
- Subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS.
- Subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system.
Exclusion
- \- Pregnancy
Key Trial Info
Start Date :
September 20 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 5 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01909492
Start Date
September 20 2013
End Date
October 5 2023
Last Update
June 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence MS Center
Portland, Oregon, United States, 97225